David C. Hastings
Independent DirectorMr. David C. Hastings, also known as Dave, CPA, is Chief Financial Officer of Trevi Therapeutics, Inc., from January 6, 2026. He was Chief Financial Officer of Arbutus Biopharma Corporation since June 11, 2018 until March 27, 2025 and served as its Chief Accounting Officer since March 31, 2019 until March 27, 2025. He joined the Arbutus Biopharma Corporation on June 11, 2018. Mr. Hastings has been an Advisor of Unilife Corporation since June 9, 2017. Previously, Mr. Hastings served as the Chief Financial Officer and Senior Vice President of Unilife Corporation from February 23, 2015 to June 9, 2017 and served as its Chief Accounting Officer and Treasurer from July 28, 2016 to June 9, 2017. Mr. Hastings served as the Chief Financial Officer and Executive Vice President of Incyte Corporation since October 2003 until October 31, 2014. During this time, Mr. Hastings oversaw all financial aspects as Incyte transitioned from research and development to commercialization following the launch of Jakafi® (ruxolitinib). He served as Vice President, Chief Financial Officer and Treasurer of Arqule Inc. from February 2000 to September 2003. He played an important role in ArQule's transition into a drug discovery and development organization. During his tenure at ArQule, he improved ArQule's access to the capital markets and completed two strategic acquisitions including, most recently, the purchase of Cyclis Pharmaceuticals Inc., a privately-held cancer therapeutics company. He was employed with Genzyme Corporation where he served as Vice President and Corporate Controller. Prior to Genzyme he served for three years as Director of finance at Sunovion Pharmaceuticals, Inc. (Formerly, Sepracor, Inc.). He was employed with PriceWaterhouseCoopers from 1985 to 1994, where he was active in several initial and follow-on public offerings for various biotechnology companies. He has been an Independent Director of Entasis Therapeutics Holdings Inc. since April 2018. He has many years of finance, accounting and operations experience in the bio-pharmaceutical industry. He has been an Independent Director of SCYNEXIS, Inc. since September 24, 2015. He had been an Independent Non-Executive Director at Vascular Biogenics Ltd. since January 3, 2018 until October 16, 2023. He served as a Director of Incyte Corporation. Mr. Hastings is a Certified Public Accountant and holds a B.A. degree in Economics from the University of Vermont.
Positions
- Company NameSCYNEXIS, Inc.Stock CodeSCYXPositionIndependent DirectorColleagues
- DGDavid Gonzalez AnguloCEO, President & Director
- GMGuy MacDonaldIndependent Chairman of the Board
- SSScott SukenickChief Legal Officer & Corporate Secretary
- SSSanjay S. SubramanianChief Financial Officer
- DGDaniella GiganteVice President of Human Resources & Information Technology
- TMTodd MingaSenior Vice President of Research & Development
- AFAnn F. HanhamIndependent Director
- AAArmando AnidoIndependent Director
- Company NameTrevi Therapeutics, Inc.Stock CodeTRVIPositionChief Financial Officer & Principal Financial OfficerColleagues
- JLJennifer L. GoodCo-Founder, CEO, President, & Director
- DPDavid P. MeekerIndependent Chairman of the Board
- JVJames V. CassellaChief Development Officer
- FSFarrell SimonChief Commercial Officer
- TRThomas R. SciasciaCo-Founder & Chief Scientific Officer
- DCDavid C. HastingsChief Financial Officer & Principal Financial Officer
- MTMichael Thomas HeffernanIndependent Director
- AMAnne M. VanLentIndependent Director
- JBJeffrey BernhardMember of Clinical Advisory Board
